Skip to main content
Premium Trial:

Request an Annual Quote

CST, AstraZeneca, GE Healthcare, Fisher Scientific, Clintrak Pharma, Molecular Devices

Premium

CST, AstraZeneca Ink Third Phosphorylation-Profiling Deal

Cell Signaling Technology has signed a third agreement with AstraZeneca to continue providing the drug maker with phosphorylation profiles and prospective biomarkers of kinase-targeted lead compounds, the company said this week.

CST announced similar agreements in January of this year and in June 2004.

According to its most recent statement, CST will use its PhosphoScan technology to provide AstraZeneca with information that could enable it to clinically develop biomarker assays for target validation and therapeutic kinase inhibitors.

CST also said that it has recently added methods for serine/threonine kinase PhosphoScan profiling to its capabilities.


GE Healthcare's Q1 Revenues Climb 10 Percent as Profit Grows 21 Percent

GE Healthcare's revenues for the first quarter of 2006 climbed 10 percent, and the segment's earnings increased 21 percent, General Electric reported this week.

For the quarter ending March 31, GE Healthcare had $3.7 billion in revenues, up from $3.3 billion during the same quarter in 2005.

GE Healthcare's earnings for the quarter amounted to $496 million, up from $409 million in the first quarter of 2005.

General Electric's total revenues for the quarter were $23.5 billion, up from $21.4 billion during the same period last year. The company reported $4.3 billion, or $.41 per share, in total earnings for the quarter, up from $4 billion, or $.37 per share, during the same quarter in 2005.

GE Healthcare did not break out its research and development expenses for the quarter.

As of March 31, GE had $53.6 billion in cash and marketable securities.


Fisher Scientific to Acquire Clintrak Pharma Services for $125M; Also Buys TC Tech

Fisher Scientific this week said it has entered into a definitive agreement to acquire privately held Clintrak Pharmaceutical Services for $125 million in cash from a group of investors led by Bear Growth Capital Partners.

Clintrak is a provider of clinical-trial generation and supply-chain management services. Fisher said that the acquisition will enhance its existing biopharma services and add complementary expertise in the area of complex clinical-trial labeling services.

Clintrak had 2005 revenue of approximately $31 million, Fisher said.

Fisher also announced this week that it has acquired privately held TC Tech, a provider of single-use, flexible bioprocessing systems for bioprocess development and production applications. Fisher did not disclose financial details of this transaction.


Molecular Devices Schedules Q1 Earnings Release

Molecular Devices said that it will announce its first quarter 2006 earnings on Thursday, April 27, after the close of regular market trading.

Senior management will hold a conference call the following day, Friday, April 28, at 8:00 am PST, to discuss operating results and other business matters.

Interested parties can find the dial-in numbers for the conference call or access a live webcast on the investor page on Molecular Devices' website, www.moleculardevices.com.